Melander A, Niklasson B, Ingemarsson I, Liedholm H, Scherstén B, Sjöberg N O
Eur J Clin Pharmacol. 1978 Nov 16;14(2):93-4. doi: 10.1007/BF00607437.
Maternal and umbilical serum concentrations of atenolol, a hydrophilic, cardioselective beta-adrenoceptor antagonist, were studied at delivery in seven cases of pregnancy hypertension. The drug had been administered to each patient for at least one week. Atenolol was detected in both maternal and umbilical serum in six cases, showing that there is transplacental passage of the drug. In the seventh case, who had stopped taking atenolol more than one day before delivery, neither maternal nor umbilical serum contained a measurable quantity of the drug. Atenolol concentration varied 3- to 6-fold between individuals, but there was no systematic difference between maternal and umbilical levels. It seems reasonable to assume that during steady state conditions the blood level of atenolol in mother and fetus is approximately equal, and that fetal accumulation of the drug does not occur.
对7例妊娠高血压患者分娩时亲水性、心脏选择性β-肾上腺素能受体拮抗剂阿替洛尔的母体血清和脐血清浓度进行了研究。每位患者均已服用该药至少一周。6例患者的母体血清和脐血清中均检测到阿替洛尔,表明该药存在经胎盘转运。在第7例患者中,其在分娩前一天多就已停用阿替洛尔,母体血清和脐血清中均未检测到可测量的该药物量。阿替洛尔浓度在个体间相差3至6倍,但母体和脐血水平之间无系统性差异。似乎有理由假定,在稳态条件下,母亲和胎儿体内阿替洛尔的血药水平大致相等,且该药物不会在胎儿体内蓄积。